MRRF

Across TCGA pan-cancer cohorts, MRRF mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MRRF data layer compared with 18 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MRRF mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MRRF expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where MRRF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.428	0.211	.008	19	view →
LUAD	DFS	Median	All	0.520	0.918	.006	11	view →
LSCC	DFS	Median	III,IV	0.894	0.494	.019	5	view →
GBM	DFS	Median	All	0.560	0.792	.027	1	view →
CCRCC	DFS	Median	III,IV	0.592	0.845	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MRRF–PDAC (DFS)

Open the PDAC breakdown →